Drug Profile
AB 452
Alternative Names: AB-452Latest Information Update: 13 Feb 2020
Price :
$50
*
At a glance
- Originator Baruch S. Blumberg Institute; Drexel University College of Medicine
- Developer Arbutus Biopharma
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis B virus replication inhibitors; Viral antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hepatitis B
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 10 Feb 2020 Discontinued - Preclinical for Hepatitis B in USA (PO)
- 05 Nov 2019 AB 452 is available for licensing as of 05 Nov 2019. http://www.arbutusbio.com/partners/partnering-licensing-opportunities.php
- 03 Oct 2019 Arbutus Biopharma withdraws a clinical trial of AB 506 and AB 452 combination therapy prior to enrolment in Hepatitis B, due to discontinuation of development of AB 506